Teriparatide and Risedronate in the Treatment of Patients with Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures

Trial Profile

Teriparatide and Risedronate in the Treatment of Patients with Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Teriparatide (Primary) ; Calcium; Risedronic acid; Vitamin D
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Acronyms VERO
  • Sponsors Eli Lilly
  • Most Recent Events

    • 09 Nov 2017 According to an Eli Lilly media release, Primary endpoint has been met (Proportion of Participants with New Vertebral Fractures).
    • 09 Nov 2017 According to an Eli Lilly media release, data for treatment with Forteo for 24 months was published in the The Lancet (Nov 2017).
    • 09 Nov 2017 Results published in the Eli Lilly media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top